Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on July 22, 2025
Daxor’s Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions
GlobeNewswire
·
July 22, 2025
Continued Integration of Daxor’s ezBVA Lab Service and On-Site Analyzers Fuels Positive Outlook Oak Ridge, TN, July 22, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces the …
NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025
GlobeNewswire
·
July 22, 2025
NAARDEN, the Netherlands and MIAMI, July 22, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at …
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
GlobeNewswire
·
July 22, 2025
SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is …
BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors
GlobeNewswire
·
July 22, 2025
CARSON CITY, Nev., July 22, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver …
aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
GlobeNewswire
·
July 22, 2025
SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase …
Health care advocates afraid of major cuts and privatization hold rally at Council of the Federation
GlobeNewswire
·
July 22, 2025
HUNTSVILLE, Ontario, July 22, 2025 (GLOBE NEWSWIRE) -- Outside the Council of the Federation and the gathering of First Ministers, public health care advocates from across Canada will be joining a rally and car cavalcade. Attendees include Health …
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
GlobeNewswire
·
July 22, 2025
Tel Aviv, July 22, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous …
Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.
GlobeNewswire
·
July 22, 2025
GARDEN CITY, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives …
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
GlobeNewswire
·
July 22, 2025
REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will …
Reunion Neuroscience Announces Publication of RE104 Phase 1 Data in The Journal of Clinical Psychopharmacology
GlobeNewswire
·
July 22, 2025
-- Phase 1 Data Highlight RE104 Favorable Safety Profile and Short Duration Psychoactive Experience -- -- Topline Results from RECONNECT Phase 2 Trial of RE104 in Postpartum Depression (PPD) Anticipated in Q3 2025 -- MORRISTOWN, N.J., July 22, 2025 (GLOBE …
Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)
GlobeNewswire
·
July 22, 2025
TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the investigator-led Phase II trial titled “Prevention Of NephroToxin Induced Acute Kidney Injury with …
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
GlobeNewswire
·
July 22, 2025
PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter …
uniQure to Announce Second Quarter 2025 Financial Results
GlobeNewswire
·
July 22, 2025
LEXINGTON, Mass. and AMSTERDAM, July 22, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2025 financial results before …
CMMB Introduces Derek Yach as New Global Health Advisor
GlobeNewswire
·
July 22, 2025
New York, New York, July 22, 2025 (GLOBE NEWSWIRE) -- Catholic Medical Mission Board (CMMB) is thrilled to announce the appointment of public health expert Derek Yach as its new global health advisor for noncommunicable diseases (NCDs) and therapeutics. …
ProMIS Neurosciences Announces Private Placement Financing
GlobeNewswire
·
July 22, 2025
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded …
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
GlobeNewswire
·
July 22, 2025
CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. ET to …
Health Canada Authorizes bioLytical’s iStatis Syphilis Test, Boosting Rapid Response to Rising Infections in Canada
GlobeNewswire
·
July 22, 2025
Now authorized for professional use in Canada, the iStatis Syphilis Antibody Test offers a fast, accurate, and portable solution to strengthen syphilis screening efforts nationwide. Health Canada authorizes the iStatis Syphilis Antibody Test for …
Santé Canada autorise le test de dépistage de la syphilis iStatis de bioLytical, afin de renforcer la réponse rapide à l’augmentation des infections au Canada
GlobeNewswire
·
July 22, 2025
Maintenant autorisé à une utilisation professionnelle au Canada, le test de dépistage des anticorps de la syphilis iStatis offre une solution rapide, précise et portable pour renforcer les efforts de dépistage de la syphilis dans tout le pays. Santé Canada …
Memo Therapeutics AG Publishes Study on its Potent Antibody for Treatment of BKPyV Infection in Kidney Transplantation
GlobeNewswire
·
July 22, 2025
PRESS RELEASE Memo Therapeutics AG Publishes Study on its Potent Antibody for Treatment of BKPyV Infection in Kidney Transplantation Novel antibody, potravitug, demonstrates high neutralization of all BKPyV serotypes with potential to transform treatment …
InspireMD to Announce Second Quarter 2025 Financial Results
GlobeNewswire
·
July 22, 2025
MIAMI, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its second quarter 2025 financial results on Tuesday, …